Articles

UC Davis, Agilent, FDA announce genome project

The 100K Genome Project to sequence microorganism genomes
Written byKelsey Kaustinen
| 2 min read

DAVIS, Calif.—A new initiative was announced today betweenthe University of California, Davis (UC Davis), Agilent Technologies and theU.S. Food and Drug Administration (FDA). The five-year project will sequencethe genomes of 100,000 infectious microorganisms in hopes of speeding thediagnosis of food-borne illnesses. Prof. Bart Weimer of the UC Davis School ofVeterinary Medicine will serve as director of the 100K Genome Project, and thesequencing will take place at the recently established BGI@UC Davis facility.Additional collaborators on the undertaking include the U.S. Centers forDisease Control and Prevention (CDC) and the U.S. Department of Agriculture'sFood Safety and Inspection Service.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.